Market by Product Type, Therapeutic Application, and End-user | Forecast 2023-2028
Triton’s research report predicts that the
market for botulinum toxin type A in India will witness a CAGR of 11.35% over the forecast period 2023-2028, garnering revenue worth $XX
by 2028.
Botulinum toxin type A is used off-label for
many conditions, including neurogenic thoracic outlet syndrome, myofascial
pain, post-herpetic neuralgia, epicondylitis, post-stroke pain, trigeminal
neuralgia, and bladder pain.
The pure form of botulinum toxin, referred to as the miraculous poison
or botulinum toxin type A, hinders the release of acetylcholine for treating
conditions such as dystonia, persistent sialorrhea, and muscle stiffness. By
injecting botulinum toxin into muscle tissue, it initiates neuromuscular
blockade and induces muscle relaxation. This effect is beneficial in addressing
disorders linked to excessive muscle activity, encompassing various types of
spasticity, hemifacial spasm, infantile cerebral palsy, tremors, tics, as well
as motility issues affecting the gastrointestinal tract and bladder. These applications
encompass the treatment of conditions like strabismus, detrusor overactivity,
cervical dystonia, post-stroke spasticity, and blepharospasm.
The widely used preparation, botulinum toxin
type A, is available in commercially viable versions in India: Botox® (Allergan
Pharmaceuticals), Botulax® (Hugel Inc), Xeomin® (Merz Pharmaceuticals),
Neuronox (Medy-Tox Inc), Boto Genie® (Bio-Med), Dysport® (Ipsen
Pharmaceuticals), and Zarbot (Gufic Biosciences).
There is a large pool of highly skilled medical
professionals, which gives them an edge in India. Compared to its counterparts
in Asia and the West, India is also cost-competitive. The low cost of
healthcare has led to increased medical tourism, attracting individuals
worldwide. Moreover, because of its relatively low cost of clinical research,
the nation has become a center for R&D activity for foreign businesses.
Triton Market Research’s report provides
in-depth insight into the India botulinum toxin type A market, along with
segmentation analysis. The detailed analysis of the market includes PEST
analysis, current market trends, regulatory framework, and insurance system & reimbursements. The segmentation analysis
includes market by product type, therapeutic application, and end-user.
The eminent companies listed in the market consist of Abbvie Inc,
Medytox Inc, Bio-Med, Gufic Biosciences Ltd, and Hugel Inc.
Market By Type, Application, E ..
VIEW REPORT
Market By Device Type, Therape ..
VIEW REPORT
Market By Type, Application, T ..
VIEW REPORT
Market By Technology, Applicat ..
VIEW REPORT
Market By Application, Type, E ..
VIEW REPORT
Market by Therapeutics, Diagno ..
VIEW REPORT
Market by Type, Application, E ..
VIEW REPORT1. INDIA
BOTULINUM TOXIN TYPE A MARKET – SUMMARY
1.1. MARKET
SIZE & FORECAST
1.2. COUNTRY
ANALYSIS
1.3. MARKET
DRIVING ASPECTS
1.3.1. GROWING
AWARENESS REGARDING NUMEROUS THERAPEUTIC APPLICATIONS OF BOTULINUM TOXIN
1.3.2. RISING
MEDICAL TOURISM IN INDIA
1.4. MARKET
RESTRAINING ASPECT
1.4.1. EASY
ACCESS TO COUNTERFEIT BOTULINUM TOXIN TYPE A PRODUCTS
2. INDIA
BOTULINUM TOXIN TYPE A MARKET OUTLOOK
2.1. PEST ANALYSIS
2.2. CURRENT
MARKET TRENDS
2.3. KEY
MARKET STRATEGIES
2.3.1. COLLABORATIONS
2.3.2. PRODUCT
LAUNCHES AND DEVELOPMENTS
2.3.3. ACQUISITIONS
2.4. POTENTIAL
FOR NEW ENTRANTS IN INDIA BOTULINUM TYPE A MARKET
2.5. MARKET
ATTRACTIVENESS INDEX
2.6. REGULATORY
FRAMEWORK
2.7. INSURANCE
SYSTEM AND REIMBURSEMENTS
2.7.1. HEALTHCARE
& INSURANCE SYSTEM
2.7.2. REIMBURSEMENT
FOR THERAPEUTIC BOTOX TREATMENT
3. INDIA
BOTULINUM TOXIN TYPE A MARKET OUTLOOK - BY PRODUCT TYPE
3.1. ABOBOTULINUMTOXIN
TYPE A
3.2. INCOBOTULINUMTOXIN
TYPE A
3.3. ONABOTULINUMTOXIN
TYPE A
4. INDIA
BOTULINUM TOXIN TYPE A MARKET OUTLOOK - BY THERAPEUTIC APPLICATION
4.1. CHRONIC
MIGRAINE
4.2. SPASTIC
DISORDERS
4.3. CERVICAL
DYSTONIA
4.4. DETRUSOR
OVERACTIVITY
4.5. OTHER
THERAPEUTIC APPLICATIONS
5. INDIA
BOTULINUM TOXIN TYPE A MARKET OUTLOOK - BY END-USER
5.1. HOSPITALS
AND CLINICS
5.2. OTHER
END-USERS
6. COMPETITIVE
LANDSCAPE
6.1. ABBVIE
INC
6.2. MEDYTOX
INC
6.3. HUGEL
INC
6.4. IPSEN
PHARMA
6.5. MERZ
PHARMA
6.6. BIO-MED
6.7. GUFIC
BIOSCIENCES LTD
7. RESEARCH
METHODOLOGY & SCOPE
7.1. RESEARCH
SCOPE & DELIVERABLES
7.2. SOURCES
OF DATA
7.3. RESEARCH
METHODOLOGY
TABLE 1: THERAPEUTIC
APPLICATIONS FOR BOTULINUM TOXIN
TABLE 2: REGULATORY FRAMEWORK
FOR INDIA BOTULINUM TOXIN TYPE A MARKET
TABLE 3: FEW IMPORTANT PUBLIC
HEALTHCARE SCHEMES IN INDIA
TABLE 4: INDIA BOTULINUM TOXIN
TYPE A MARKET, BY PRODUCT TYPE, 2023-2028 (IN $ MILLION)
TABLE 5: INDIA BOTULINUM TOXIN
TYPE A MARKET, BY THERAPEUTIC APPLICATION, 2023-2028 (IN $ MILLION)
TABLE 6: INDIA BOTULINUM TOXIN
TYPE A MARKET, BY END-USER, 2023-2028 (IN $ MILLION)
TABLE 7: LIST OF BOTULINUM
TOXIN TYPE A MARKET COLLABORATIONS
TABLE 8: LIST OF BOTULINUM
TOXIN TYPE A MARKET PRODUCT LAUNCHES & DEVELOPMENTS
TABLE 9: LIST OF BOTULINUM
TOXIN TYPE A MARKET ACQUISITIONS
FIGURE
1: MARKET ATTRACTIVENESS INDEX
FIGURE
2: INDIA BOTULINUM TOXIN TYPE A MARKET, BY PRODUCT TYPE, 2022 & 2028 (IN %)
FIGURE
3: INDIA BOTULINUM TOXIN TYPE A MARKET, BY ABOBOTULINUMTOXIN TYPE A, 2023-2028
(IN $ MILLION)
FIGURE
4: INDIA BOTULINUM TOXIN TYPE A MARKET, BY INCOBOTULINUMTOXIN TYPE A, 2023-2028
(IN $ MILLION)
FIGURE
5: INDIA BOTULINUM TOXIN TYPE A MARKET, BY ONABOTULINUMTOXIN TYPE A, 2023-2028
(IN $ MILLION)
FIGURE
6: INDIA BOTULINUM TOXIN TYPE A MARKET, BY THERAPEUTIC APPLICATION, 2022 &
2030 (IN %)
FIGURE
7: INDIA BOTULINUM TOXIN TYPE A MARKET, BY CHRONIC MIGRAINE, 2023-2028 (IN $
MILLION)
FIGURE
8: INDIA BOTULINUM TOXIN TYPE A MARKET, BY SPASTIC DISORDERS, 2023-2028 (IN $
MILLION)
FIGURE
9: INDIA BOTULINUM TOXIN TYPE A MARKET, BY CERVICAL DYSTONIA, 2023-2028 (IN $
MILLION)
FIGURE
10: INDIA BOTULINUM TOXIN TYPE A MARKET, BY DETRUSOR OVERACTIVITY, 2023-2028
(IN $ MILLION)
FIGURE
11: INDIA BOTULINUM TOXIN TYPE A MARKET, BY OTHER THERAPEUTIC APPLICATIONS,
2023-2028 (IN $ MILLION)
FIGURE
12: INDIA BOTULINUM TOXIN TYPE A MARKET, BY END-USER, 2022 & 2030 (IN %)
FIGURE
13: INDIA BOTULINUM TOXIN TYPE A MARKET, BY HOSPITALS AND CLINICS, 2023-2028
(IN $ MILLION)
FIGURE
14: INDIA BOTULINUM TOXIN TYPE A MARKET, BY OTHER END-USERS, 2023-2028 (IN $
MILLION)